{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:43:16Z","timestamp":1792827796967,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Leprosy is an ancient infectious disease with an annual global incidence of around 200,000 over the past decade. Since 2018, the World Health Organization (WHO) recommends single-dose rifampicin as post-exposure prophylaxis (SDR-PEP) for contacts of leprosy patients. The Post ExpOsure Prophylaxis for Leprosy (PEOPLE) trial evaluated PEP with a double dose of rifampicin in Comoros and Madagascar. Preliminary results of this trial show some reduction in leprosy incidence in intervention villages but a stronger regimen may be beneficial. The objective of the current Bedaquiline Enhanced ExpOsure Prophylaxis for LEprosy trial (BE-PEOPLE) is to explore effectiveness of a combination of bedaquiline and rifampicin as PEP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>BE-PEOPLE is a cluster-randomized trial in which 44 clusters in Comoros will be randomized to two study arms. Door-to-door screening will be conducted annually during four years, leprosy patients identified will be offered standard of care treatment. Based on study arm, contacts aged five years and above and living within a 100-meter radius of an index case will either receive bedaquiline (400-800\u00a0mg) and rifampicin (150-600\u00a0mg) or only rifampicin (150\u2013600\u00a0mg). Contacts aged two to four years will receive rifampicin only. Household contacts randomized to the bedaquiline plus rifampicin arm will receive a second dose four weeks later. Incidence rate ratios of leprosy comparing contacts who received either of the PEP regimens will be the primary outcome. We will monitor resistance to rifampicin and\/or bedaquiline through molecular surveillance in all incident tuberculosis and leprosy patients nationwide. At the end of the study, we will assess anti-<jats:italic>M. leprae<\/jats:italic> PGL-I IgM seropositivity as a proxy for the population burden of <jats:italic>M. leprae<\/jats:italic> infection in 8 villages (17,000 individuals) that were surveyed earlier as part of the PEOPLE trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The COLEP trial on PEP in Bangladesh documented a reduction of 57% in incidence of leprosy among contacts treated with SDR-PEP after two years, which led to the WHO recommendation of SDR-PEP. Preliminary results of the PEOPLE trial show a lesser reduction in incidence. The BE-PEOPLE trial will explore whether reinforcing SDR-PEP with bedaquiline increases effectiveness and more rapidly reduces the incidence of leprosy, compared to SDR-PEP alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT05597280. Protocol version 5.0 on 28 October 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08290-0","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:31:40Z","timestamp":1683703900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Protocol, rationale and design of BE-PEOPLE (Bedaquiline enhanced exposure prophylaxis for LEprosy in the Comoros): a cluster randomized trial on effectiveness of rifampicin and bedaquiline as post-exposure prophylaxis of leprosy contacts"],"prefix":"10.1186","volume":"23","author":[{"given":"Assoumani","family":"Younoussa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said Nourdine","family":"Samidine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auke T.","family":"Bergeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Piubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissad","family":"Attoumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silahi Halifa","family":"Grillone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Marijke","family":"Braet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Tsoumanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Baco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboubacar","family":"Mzembaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahara","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Amidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Grillone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rian","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Corstjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimer","family":"Ortuno-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"Hoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Geluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epco","family":"Hasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"11","key":"8290_CR1","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/cid\/ciw570","volume":"63","author":"S Araujo","year":"2016","unstructured":"Araujo S, Freitas LO, Goulart LR, Goulart IM. Molecular evidence for the Aerial Route of infection of Mycobacterium leprae and the role of asymptomatic carriers in the persistence of Leprosy. Clin Infect Dis. 2016;63(11):1412\u201320.","journal-title":"Clin Infect Dis"},{"key":"8290_CR2","unstructured":"Hansen GHA. Unders\u00f8gelser Ang\u00e5ende Spedalskhedens \u00c5rsager (Investigations concerning the etiology of leprosy in Norwegian). Norsk Mag Laegervidenskaben 1874(4):88."},{"issue":"6142","key":"8290_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.1238286","volume":"341","author":"VJ Schuenemann","year":"2013","unstructured":"Schuenemann VJ, Singh P, Mendum TA, Krause-Kyora B, Jager G, Bos KI, et al. Genome-wide comparison of medieval and modern Mycobacterium leprae. Science. 2013;341(6142):179\u201383.","journal-title":"Science"},{"issue":"1","key":"8290_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.47276\/lr.85.1.36","volume":"85","author":"S Sermrittirong","year":"2014","unstructured":"Sermrittirong S, Van Brakel WH. Stigma in leprosy: concepts, causes and determinants. Lepr Rev. 2014;85(1):36\u201347.","journal-title":"Lepr Rev"},{"issue":"2","key":"8290_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/jinf.2000.0698","volume":"41","author":"CM Smith","year":"2000","unstructured":"Smith CM, Smith WC. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal immunology of Leprosy. J Infect. 2000;41(2):137\u201342.","journal-title":"J Infect"},{"key":"8290_CR6","unstructured":"World Health Organization. Leprosy. Global situation 2002 [updated Jan 4. 2002\/01\/26:[1\u20138]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/231735\/WER7701.PDF?sequence=1&isAllowed=y."},{"key":"8290_CR7","unstructured":"World Health Organization. Global leprosy (Hansen disease) update, 2021: moving towards interruption of transmission Geneva: WHO; 2022 [24]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/362411\/WER9736-eng-fre.pdf."},{"issue":"4","key":"8290_CR8","doi-asserted-by":"publisher","first-page":"e0003658","DOI":"10.1371\/journal.pntd.0003658","volume":"9","author":"WC Smith","year":"2015","unstructured":"Smith WC, van Brakel W, Gillis T, Saunderson P, Richardus JH. The missing millions: a threat to the elimination of leprosy. PLoS Negl Trop Dis. 2015;9(4):e0003658.","journal-title":"PLoS Negl Trop Dis"},{"key":"8290_CR9","unstructured":"World Health Organization. Global Leprosy Strategy 2016\u20132020. Accelerating towards a leprosy-free world New Delhi: WHO Library Catologuing-in-Publication data; 2016 [Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208824\/9789290225096_en.pdf?sequence=14&isAllowed=y."},{"key":"8290_CR10","first-page":"106","volume-title":"Guidelines for the diagnosis, treatment and Prevention of Leprosy","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Guidelines for the diagnosis, treatment and Prevention of Leprosy. New Delhi: Regional Office for South-East Asia; 2018. p. 106."},{"issue":"7647","key":"8290_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/bmj.39500.885752.BE","volume":"336","author":"FJ Moet","year":"2008","unstructured":"Moet FJ, Pahan D, Oskam L, Richardus JH. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008;336(7647):761\u20134.","journal-title":"BMJ"},{"key":"8290_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clinbiochem.2019.01.007","volume":"66","author":"PLAM Corstjens","year":"2019","unstructured":"Corstjens PLAM, van Hooij A, Tjon Kon Fat EM, Alam K, Vrolijk LB, Dlamini S, et al. Fingerstick test quantifying humoral and cellular biomarkers indicative for M. leprae infection. Clin Biochem. 2019;66:76\u201382.","journal-title":"Clin Biochem"},{"issue":"1","key":"8290_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1186\/s12879-019-4649-0","volume":"19","author":"N Ortuno-Gutierrez","year":"2019","unstructured":"Ortuno-Gutierrez N, Younoussa A, Randrianantoandro A, Braet S, Cauchoix B, Ramboarina S, et al. Protocol, rationale and design of PEOPLE (Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar): a cluster randomized trial on effectiveness of different modalities of implementation of post-exposure prophylaxis of leprosy contacts. BMC Infect Dis. 2019;19(1):1033.","journal-title":"BMC Infect Dis"},{"key":"8290_CR14","doi-asserted-by":"crossref","unstructured":"Marijke Braet S, Jouet A, Aubry A, Van Dyck-Lippens M, Lenoir E, Assoumani Y et al. Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe. 2022.","DOI":"10.1016\/S2666-5247(22)00117-3"},{"issue":"3","key":"8290_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5588\/ijtld.19.0704","volume":"24","author":"E Hasker","year":"2020","unstructured":"Hasker E, Assoumani Y, Mzembaba A, Zakir AM, Ortuno-Gutierrez N, de Jong BC. Using a geographic information system as a management tool for tuberculosis control. Int J tuberculosis lung disease: official J Int Union against Tuberculosis Lung Disease. 2020;24(3):354\u20136.","journal-title":"Int J tuberculosis lung disease: official J Int Union against Tuberculosis Lung Disease"},{"key":"8290_CR16","unstructured":"World Health Organization. Global tuberculosis report 2022. Tuberculosis profile: Comoros Geneva: WHO. ; 2022 [Available from: https:\/\/worldhealthorg.shinyapps.io\/tb_profiles\/?_inputs_&entity_type=%22country%22&lan=%22EN%22&iso2=%22KM%22."},{"key":"8290_CR17","unstructured":"World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy New Delhi: World Health Organization, Regional Office for South-East Asia. ; 2018 [Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274127\/9789290226383-eng.pdf?ua=1."},{"issue":"1","key":"8290_CR18","doi-asserted-by":"publisher","first-page":"8868","DOI":"10.1038\/s41598-017-07803-7","volume":"7","author":"A van Hooij","year":"2017","unstructured":"van Hooij A, Tjon Kon Fat EM, van den Eeden SJF, Wilson L, Batista da Silva M, Salgado CG, et al. Field-friendly serological tests for determination of M. leprae-specific antibodies. Sci Rep. 2017;7(1):8868.","journal-title":"Sci Rep"},{"key":"8290_CR19","unstructured":"Hooij Av. Development of immunodiagnostic tests for leprosy: from biomarker discovery to application in endemic areas. Leiden University; 2021."},{"key":"8290_CR20","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3389\/fmicb.2020.01220","volume":"11","author":"M Tio-Coma","year":"2020","unstructured":"Tio-Coma M, Avanzi C, Verhard EM, Pierneef L, van Hooij A, Benjak A, et al. Genomic characterization of Mycobacterium leprae to explore transmission patterns identifies New Subtype in Bangladesh. Front Microbiol. 2020;11:1220.","journal-title":"Front Microbiol"},{"issue":"5","key":"8290_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1128\/AAC.02243-12","volume":"57","author":"AH Diacon","year":"2013","unstructured":"Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother. 2013;57(5):2199\u2013203.","journal-title":"Antimicrob Agents Chemother"},{"key":"8290_CR22","doi-asserted-by":"crossref","unstructured":"Pieterman ED, Sarink MJ, Sala C, Cole ST, de Steenwinkel JEM, Bax HI. Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro. Antimicrob Agents Chemother. 2020;64(7).","DOI":"10.1128\/AAC.00280-20"},{"issue":"5","key":"8290_CR23","doi-asserted-by":"publisher","first-page":"e0196756","DOI":"10.1371\/journal.pone.0196756","volume":"13","author":"RS Wallis","year":"2018","unstructured":"Wallis RS, Good CE, O\u2019Riordan MA, Blumer JL, Jacobs MR, Griffiss JM, et al. Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: a randomized controlled trial. PLoS ONE. 2018;13(5):e0196756.","journal-title":"PLoS ONE"},{"issue":"2","key":"8290_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1128\/AAC.04171-14","volume":"59","author":"H Winter","year":"2015","unstructured":"Winter H, Egizi E, Murray S, Erondu N, Ginsberg A, Rouse DJ, et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015;59(2):1219\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"8290_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ije\/28.2.319","volume":"28","author":"RJ Hayes","year":"1999","unstructured":"Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol. 1999;28(2):319\u201326.","journal-title":"Int J Epidemiol"},{"key":"8290_CR26","unstructured":"WHO. Towards zero leprosy Delhi2021 [Available from: https:\/\/www.who.int\/publications\/i\/item\/9789290228509."},{"issue":"2","key":"8290_CR27","doi-asserted-by":"publisher","first-page":"e0009146","DOI":"10.1371\/journal.pntd.0009146","volume":"15","author":"AT Taal","year":"2021","unstructured":"Taal AT, Blok DJ, van Brakel WH, de Vlas SJ, Richardus JH. Number of people requiring post-exposure prophylaxis to end leprosy: a modeling study. PLoS Negl Trop Dis. 2021;15(2):e0009146.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"8290_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4269\/ajtmh.2005.72.443","volume":"72","author":"MI Bakker","year":"2005","unstructured":"Bakker MI, Hatta M, Kwenang A, Van Benthem BHB, Van Beers SM, Klatser PR, et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg. 2005;72(4):443\u20138.","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"8290_CR29","doi-asserted-by":"publisher","first-page":"e0006910","DOI":"10.1371\/journal.pntd.0006910","volume":"12","author":"I Khoudri","year":"2018","unstructured":"Khoudri I, Elyoussfi Z, Mourchid Y, Youbi M, Bennani Mechita N, Abouqal R, et al. Trend analysis of leprosy in Morocco between 2000 and 2017: evidence on the single dose rifampicin chemoprophylaxis. PLoS Negl Trop Dis. 2018;12(12):e0006910.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08290-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T07:35:42Z","timestamp":1683704142000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08290-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8290"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08290-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"24 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The BE-PEOPLE trial was approved by \u2018Comit\u00e9 National d\u2019Ethique pour les Sciences de la Vie et de la Sant\u00e9\u2019 (CNESS) (R\u00e9f.N\u00b023\/03\/CNESS\/PR) as well as by the as well as by the \u2018Direction G\u00e9n\u00e9rale de la Sant\u00e9\u2019 (R\u00e9f.N\u00b023\/33\/MSSPSPG\/DGS) in the Union of Comoros. Approval was also received from the Institutional Review Board (IRB) of the Institute of Tropical Medicine (ITM). In addition, the study has been approved by the Ethics Committee (EC) of the University of Antwerp Hospital in Antwerp. Written individual informed consent will be obtained from all participants included in the study. As the legal age of consent in Comoros is 18 years old, for participants between 2 and 18 years old informed consent of the parents or guardian will be sought. Consent information will be read to illiterate participants and written informed consent will be obtained from their respective legal authorized representative. Prior to the start, this study has been included in the Clinicaltrials.gov public registry (NCT05597280, on 28 October 2022, ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}